Abstract
The recent introduction of molecular biology methods to pharmacology, to assess how DNA sequence variations can influence the response of an individual to a drug, has opened new dimensions in the evidence based analysis of goals, risks and benefits of drug therapy. The development of diagnostic test systems to identify patients at increased risk of adverse drug reactions, the application of genomic technologies to drug development, and the clarification of the mechanisms of drug action on cells represent actual challenges for both clinicians and researchers. In this review, we emphasize on the investigative tools of molecular biology-based pharmacology with particular reference to the development of single nucleotide polymorphisms (SNPs) and new developing trends of this technology. Keywords: restriction fragment length polymorphisms, single nucleotide polymorphisms, polymerase chain reaction, genotyping, dna microarray, pharmacogenomics, pharmacogenetics
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
